BioNTech CEO Ugur Sahin sells 73K shares
BioNTech CEO Ugur Sahin reported 73,000 share sales under a Rule 10b5-1 plan while retaining over 39 million shares held indirectly.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
BioNTech SE (BNTX) reported that Chief Executive Officer and ten percent owner Ugur Sahin sold ordinary shares in two open-market or private transactions under a pre-arranged Rule 10b5-1 trading plan established on June 3, 2026. On September 8 and 9, 2026 he sold an aggregate of 73,000 ordinary shares. An indirectly held position of 39,218,111 ordinary shares, mainly through Medine GmbH, is reported after these transactions.
Insider Trade Summary 10b5-1
Net Seller: 73,000 shares
Net Sell
2 txns
Insider
Sahin Ugur
Role
Chief Executive Officer
Sold
73,000 shs ($7.19M)
Share of Position Sold
9.3%
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Sale | Ordinary Shares | 36,000 | $97.7818 | $3.52M |
| Sale | Ordinary Shares | 37,000 | $99.2032 | $3.67M |
| Holding | Ordinary Shares F1 | -- | -- | -- |
Holdings After Transaction:
Ordinary Shares — 708,709 shares (Direct);
Ordinary Shares — 39,218,111 shares (Indirect, See Footnote)
Holdings Before and After:
Ordinary Shares, 781,709 to 708,709 shares (Direct)
Footnotes (1)
- F1. The ordinary shares are held by Medine GmbH. The reporting person is the sole shareholder of Medine GmbH. 106,721 of the ordinary shares noted herein are held for the benefit of an individual under a trust arrangement, pursuant to which Medine GmbH exercises voting power, but not dispositive power, over such ordinary shares for so long as such ordinary shares are held in trust. The reporting person may be deemed to beneficially own the ordinary shares held by Medine GmbH.
Key Figures
Shares sold September 9, 2026: 36,000 shares
Shares sold September 8, 2026: 37,000 shares
Total shares sold: 73,000 shares
+4 more
7 metrics
Shares sold September 9, 2026
36,000 shares
Ordinary shares sold in open-market or private transaction at $97.7818 per share
Shares sold September 8, 2026
37,000 shares
Ordinary shares sold in open-market or private transaction at $99.2032 per share
Total shares sold
73,000 shares
Aggregate of September 8 and 9, 2026 ordinary share sales
Sale price September 9, 2026
$97.7818 per share
Price for 36,000 ordinary shares sold
Sale price September 8, 2026
$99.2032 per share
Price for 37,000 ordinary shares sold
Indirect holdings after transaction
39,218,111 shares
Ordinary shares held indirectly, reported as held by Medine GmbH
Shares in trust arrangement
106,721 shares
Ordinary shares held for the benefit of an individual under a trust where Medine GmbH has voting but not dispositive power
Key Terms
Rule 10b5-1 trading plan, ten percent owner, beneficially own, dispositive power, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
ten percent owner regulatory
"Ugur Sahin is identified as Chief Executive Officer and ten percent owner"
beneficially own regulatory
"The reporting person may be deemed to beneficially own the ordinary shares held by Medine GmbH"
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
dispositive power financial
"Medine GmbH exercises voting power, but not dispositive power, over such ordinary shares"
Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.
voting power financial
"Medine GmbH exercises voting power, but not dispositive power, over such ordinary shares"
Voting power is the ability shareholders have to influence a company's major decisions—like electing the board, approving mergers, or changing corporate rules—based on the voting rights attached to the shares they hold. For investors it matters because greater voting power is like holding more keys to a building: it gives you a stronger say over management choices and the company’s strategy, which can affect future value and risk.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did BioNTech (BNTX) report for CEO Ugur Sahin?
The report shows that CEO Ugur Sahin sold 73,000 ordinary shares of BioNTech SE in open-market or private transactions on September 8 and 9, 2026, as disclosed in a Form 4 insider filing.
What does the trust arrangement in Ugur Sahin’s BioNTech (BNTX) holdings involve?
The filing notes that 106,721 ordinary shares are held for the benefit of an individual under a trust arrangement. Medine GmbH exercises voting power, but not dispositive power, over these shares while they are held in trust.
Does the Form 4 say Ugur Sahin remains a ten percent owner of BioNTech (BNTX)?
Yes. Ugur Sahin is identified as both Chief Executive Officer and a ten percent owner of BioNTech SE in the Form 4 reporting these transactions.
AI-generated analysis. How Rhea-AI works. Not financial advice.
